RESUMEN

We have synthesised a novel cholesterol-based cationic lipid to promote DNA transfer in cells. This lipid, dimethyl hydroxyethyl aminopropane carbamoyl cholesterol iodide (DMHAPC-Chol) contains a biodegradable carbamoyl linker and a hydroxyethyl group in the polar amino head moiety and is characterised by NMR. Liposomes prepared from this lipid and dioleoyl phosphatidyl ethanolamine (DOPE) in equimolar proportion showed a weak cytotoxicity as revealed by MTT assays and are efficient to deliver plasmids DNA evaluated by the expression of reporter genes in vitro and in vivo. In this paper, we present an original method to determine the lipid concentration based on the colorimetric detection of the colipid DOPE and the measure of the molar ratio DOPE/cationic lipid in the liposome by FTIR spectroscopy. The liposomes and lipid/DNA complexes structures were characterized by transmission electron microscopy (TEM) and by quasi-elastic light scattering (QLS). TEM indicated that the complexes correspond to aggregates containing globular substructures with liposomes size. The method of immuno-gold labelling was used to detect plasmid in the complex and reveals the presence of DNA inside the aggregates. Transfection results showed efficient DNA transfer depending on the charge ratio and liposomes conditioning. Gel retardation results indicated that at a molar charge ratio between X = 1.5 and X = 2.5 (depending on the liposome conditioning), all DNA was taken by liposomes. We showed that conditioning by freeze-drying (lyophilization) facilitates storage and improves transfection efficiency. When the liposomes were lyophilized prior to DNA addition or when the complexes were subjected to freeze-thawing cycles, the obtained complexes showed a transfection with levels enhanced up to four and five-fold respectively for the lyophilized liposomes and freeze-thawed complexes. NMR was used to characterize the modifications under freezing which showed an effect on 31P spectra.

Asunto(s)

Colesterol/administración & dosificación , ADN/administración & dosificación , Sistemas de Liberación de Medicamentos/métodos , Animales , Cationes , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/genética , Colesterol/genética , Colesterol/toxicidad , ADN/genética , ADN/toxicidad , Relación Dosis-Respuesta a Droga , Femenino , Liofilización , Lípidos/administración & dosificación , Lípidos/genética , Lípidos/toxicidad , Liposomas , Ratones , Ratones Desnudos , Fosfatidiletanolaminas/administración & dosificación , Fosfatidiletanolaminas/genética , Fosfatidiletanolaminas/toxicidad , Transfección/métodos

RESUMEN

This paper reports results concerning the transfection of gliosarcoma cells 9L using an original cholesterol-based cationic liposome as carrier. This cationic liposome was prepared from triethyl aminopropane carbamoyl cholesterol (TEAPC-Chol) and a helper lipid, dioleoyl phosphatidyl ethanolamine (DOPE). The used concentration of liposome was not cytotoxic as revealed by the MTT test. TEAPC-Chol/DOPE liposomes allowed the plasmids encoding reporter genes to enter the nucleus as observed both by electron microscopy and functionality tests using fluorescence detection of green fluorescent protein (GFP) and luminometric measurements of luciferase activity. By changing the cationic lipid/DNA molar charge ratio, optimal conditions were determined. Further, improvement of the transfection level has been obtained by either precondensing plasmid DNA with poly-L-lysine or by adding polyethylene glycol (PEG) in the transfection medium. The optimal conditions determined are different depending on whether the transfection is made with cells in culture or with tumors induced by subcutaneous (s.c.) injection of cells in Nude mice. For in vivo assays, a simple method to overcome the interference of haemoglobin with the chemiluminescence intensity of luciferase has been used. These results would be useful for gaining knowledge about the potential for the cationic liposome TEAPC-Chol/DOPE to transfect brain tumors efficiently.

Asunto(s)

Colesterol , Técnicas de Transferencia de Gen , Liposomas , Animales , Supervivencia Celular , Colesterol/análogos & derivados , Colesterol/toxicidad , Proteínas Fluorescentes Verdes , Proteínas Luminiscentes/genética , Ratones , Ratones Desnudos , Microscopía Electrónica , Microscopía de Contraste de Fase , Trasplante de Neoplasias , Plásmidos/análisis , Polietilenglicoles , Polilisina , Ratas , Células Tumorales Cultivadas

RESUMEN

In vitro and in vivo transgene expression in B16-F10 melanoma cells has been investigated using an original cationic liposome prepared with triethyl aminopropane carbamoyl cholesterol iodide (TEAPC-Chol) as carrier. TEAPC-Chol/DOPE (dioleoyl phosphatidyl ethanolamine) liposomes are unilamellar, very stable and not toxic in the used concentration range. The yield in complexation with plasmid DNA can reach 100% even in the presence of fetal calf serum. The transfection level has been evaluated by luminometric measurements of luciferase expression. With TEAPC-Chol/DOPE (1:1) liposomes, a relatively high transfection level in B16-F10 cells has been observed comparing to commercial reagents. For in vivo assays, the transfection level in tumors induced in Nude mice has been optimized by studying the effects of charge ratio, of the helper lipid and of the injection volume. Results showed that TEAPC-Chol/DOPE (1:1) liposomes have improved 10-fold transfection level versus direct gene transfer of free DNA.

Asunto(s)

Técnicas de Transferencia de Gen , Liposomas , Melanoma Experimental/genética , Animales , Supervivencia Celular/efectos de los fármacos , Colesterol , Cromatografía en Gel , ADN de Neoplasias/biosíntesis , ADN de Neoplasias/genética , Femenino , Citometría de Flujo , Genes Reporteros/genética , Proteínas Fluorescentes Verdes , Inyecciones Espinales , Proteínas Luminiscentes/metabolismo , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Plásmidos/genética , Sales de Tetrazolio , Tiazoles , Transfección

RESUMEN

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that need to be activated before they can function to initiate primary and secondary immune responses in vivo. DCs are also specialized to maintain peripheral tolerance to self after uptake of apoptotic material, likely corresponding to both apoptotic bodies and whole apoptotic cells. Here, we report that murine bone marrow-derived DCs can be activated in vitro by exogenous signals received from apoptotic leukemia cells expressing on the cell surface a model tumor-associated antigen. Injected in vivo, these exogenously activated DCs can function as adjuvants to protect mice against leukemia by stimulating an antigen-specific cellular-mediated cytotoxic immune response. To our knowledge, this is the first report indicating that DCs loaded with apoptotic leukemia cells protect mice against leukemia development.

Asunto(s)

Apoptosis/fisiología , Vacunas contra el Cáncer/inmunología , Células Dendríticas/inmunología , Leucemia L1210/inmunología , Animales , Antígenos de Neoplasias/inmunología , Células de la Médula Ósea/citología , Células de la Médula Ósea/inmunología , Antígenos CD4/genética , Antígenos CD4/inmunología , Citotoxicidad Inmunológica , Femenino , Técnicas de Transferencia de Gen , Humanos , Inmunoterapia Adoptiva , Leucemia L1210/genética , Leucemia L1210/prevención & control , Ratones , Ratones Endogámicos DBA , Fagocitosis/inmunología

RESUMEN

We have investigated the delivery and the pathway in tumoral MCF7 cells of DNA carried by liposomes prepared from (trimethyl aminoethane carbamoyl cholesterol iodide (TMAE-Chol), a cholesterol-based cationic lipid with a quaternary ammonium on the polar head. The structure of DNA-liposome complexes depends on the length of DNA and on the lipid-DNA charge ratio X. Spherical beads constitute fine structures of the observed complexes even when they appear as aggregates. For oligonucleotide transfer, dissociation from liposomes after transfection, penetration of the oligonucleotides into nuclei, and a long resident time were observed. For plasmid transfer, a correlation between the variation in the transfection level and the ultrastructure of complexes was demonstrated. The results showed a cellular route of lipid/plasmid complexes from the beginning by endocytosis, entrapped into endosomes, released by the latter until entry in the perinuclear area, and then penetration of plasmids inside the nuclei resulting in the observed expression of the beta-galactosidase gene.

Asunto(s)

Colesterol/metabolismo , ADN/administración & dosificación , ADN/metabolismo , Liposomas/química , Liposomas/metabolismo , Transfección/métodos , Transporte Biológico , Cationes/metabolismo , Núcleo Celular/metabolismo , Núcleo Celular/ultraestructura , ADN/genética , ADN/ultraestructura , Endocitosis , Endosomas/metabolismo , Endosomas/ultraestructura , Fluoresceína , Vectores Genéticos/administración & dosificación , Vectores Genéticos/genética , Vectores Genéticos/metabolismo , Vectores Genéticos/ultraestructura , Humanos , Microscopía Confocal , Microscopía Electrónica , Oligodesoxirribonucleótidos/administración & dosificación , Oligodesoxirribonucleótidos/genética , Oligodesoxirribonucleótidos/metabolismo , Células Tumorales Cultivadas , beta-Galactosidasa/genética , beta-Galactosidasa/metabolismo

RESUMEN

Despite extensive surgery for glioblastoma, residual tumor cells always lead to relapse. Gene therapy based on retrovirus-mediated gene transfer of herpes simplex virus type 1 thymidine kinase (HSV-1 TK), which specifically sensitizes dividing cells to ganciclovir (GCV) toxicity, may help eradicate such cells. During glioblastoma surgery, HSV-1 TK retroviral vector-producing cells (M11) were injected into the surgical cavity margins after tumor debulking. After a 7-day transduction period, GCV was administered for 14 days. Safety was assessed by clinical and laboratory evaluations, and efficacy was assessed by MRI-based relapse-free survival at month 4 and by overall survival. Twelve patients with recurrent glioblastoma were treated without serious adverse events related to M11 cell administration or GCV. Quality of life was not negatively influenced by this treatment. Overall median survival was 206 days, with 25% of the patients surviving longer than 12 months. At 4 months after treatment, 4 of 12 patients had no recurrence; their median overall survival was 528 days, compared with 194 days for patients with recurrence (p=0.03 by the log rank test). One patient is still free of detectable recurrence, steroid free and independent, 2.8 years after treatment. Thus, brain injections of M11 retroviral vector-producing cells for glioblastoma HSV-1 TK gene therapy were well tolerated and associated with significant therapeutic responses. These results warrant further development of this therapeutic strategy in brain tumor, including recurrent glioblastoma.

Asunto(s)

Neoplasias Encefálicas/terapia , Glioblastoma/terapia , Herpesvirus Humano 1/genética , Timidina Quinasa/genética , Adulto , Neoplasias Encefálicas/diagnóstico por imagen , Supervivencia sin Enfermedad , Femenino , Ganciclovir/uso terapéutico , Glioblastoma/diagnóstico por imagen , Herpesvirus Humano 1/enzimología , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Radiografía , Recurrencia

RESUMEN

We performed a dose-escalating phase I/II study of retrovirus-mediated herpes simplex virus type 1 thymidine kinase (HSV-1-TK) suicide gene therapy for metastatic melanoma. HSV-1 TK expression, which specifically sensitizes transduced and bystander cancer cells to ganciclovir (GCV) toxicity, was mediated by one (four patients, first dose step) to three (four patients, second dose step) injections of "M11" retrovirus vector-producing cells in melanoma cutaneous nodules. After a 7-day period allowed for cancer cell transduction, GCV was administered for 14 days. Safety was assessed by clinical and laboratory evaluations, and efficacy was assessed by tumor measurements and histology. M11 doses ranged from 76 to 1247 x 10(6) cells. Treatment-related adverse events were mild and transient, limited to inflammatory skin reactions at injection and fever on repeated injections. Plasma GCV was in the active range (>0.2 microg/ml); transgene was detected by polymerase chain reaction in three of six patients; treated tumor size was moderately affected under GCV as compared with untreated tumors, although 2 weeks after GCV administration important (>50%) treated-tumor necrosis was evidenced on histology in three of eight patients. All patients showed disease progression on long-term follow-up. Thus, M11-mediated HSV-1 TK gene therapy was well tolerated over a wide dose range. The limited tumor response is likely to be related to poor gene transfer efficiency. However, necrosis following GCV administration in transduced tumors indicates a potential for treatment efficacy.

Asunto(s)

Terapia Genética , Herpesvirus Humano 1/genética , Melanoma/terapia , Timidina Quinasa/genética , Adulto , Anciano , Femenino , Ganciclovir/uso terapéutico , Terapia Genética/efectos adversos , Herpesvirus Humano 1/enzimología , Humanos , Masculino , Melanoma/patología , Persona de Mediana Edad , Metástasis de la Neoplasia

RESUMEN

We examined the efficacy of suicide gene therapy for nitrosomethylurea-induced mammary tumors in rats. Individual tumors were directly injected with a retrovirus-producing cell line that releases retroviral vectors that transduce the herpes simplex virus type 1 thymidine kinase (HSV1-TK) gene. HSV1-TK specifically converts the nucleoside analogue ganciclovir (GCV) into a toxic metabolite. Compared to control rats receiving saline, we observed a significant tumor regression of the injected tumors following GCV administration, accompanied by a stromal inflammation and an extensive lymphocyte infiltration invading the tumor epithelium. It is noteworthy that the neighboring uninjected tumors also regressed, demonstrating the occurrence of a distant bystander effect. This is the first demonstration that HSV1-TK/GCV can efficiently treat multiple solid tumors directly generated from an epithelial tissue.

Asunto(s)

Antimetabolitos/uso terapéutico , Ganciclovir/uso terapéutico , Terapia Genética/métodos , Herpesvirus Humano 1/enzimología , Neoplasias Mamarias Experimentales/terapia , Timidina Quinasa/uso terapéutico , Animales , Antimetabolitos/metabolismo , Carcinógenos , Femenino , Ganciclovir/metabolismo , Herpesvirus Humano 1/genética , Neoplasias Mamarias Experimentales/inducido químicamente , Neoplasias Mamarias Experimentales/patología , Metilnitrosourea , Neoplasias Primarias Múltiples/inducido químicamente , Neoplasias Primarias Múltiples/patología , Neoplasias Primarias Múltiples/terapia , Ratas , Ratas Sprague-Dawley , Timidina Quinasa/genética , Timidina Quinasa/metabolismo , Transfección

RESUMEN

We recently described a novel nonviral/viral vector for gene transfer, the plasmovirus (Noguiez-Hellin P, Robert-le Meur M, Laune S, et al. C R Acad Sci Paris, Sciences de la Vie. 1996;319:45-50; Noguiez-Hellin P, Robert-le Meur M, Salzmann J-L, et al. Proc Natl Acad Sci USA. 1996;93:4175-4180). Plasmoviruses are plasmids capable of expressing all the viral genes required for generating infectious particles and packaging a defective genome containing a transgene. Transfected as plasmids, plasmoviruses transform the transduced cells into packaging cells that release infectious replication-defective retrovirus vectors (RV) containing a transgene, which are capable of infecting nearby cells. We previously showed that such a vector can efficiently "propagate" the transgene after transfection. Here we examine in greater detail the different steps of plasmovirus replication in vitro in human (143 B TK-) and murine (NIH 3T3 TK-) cells. Molecular-biological analysis revealed plasmovirus-coded protein expression starting from 24 hours post-transfection, followed by the detection of infectious RV 48 hours post-transfection. The gag proteins were correctly processed in the released particles. Electron microscopic analysis revealed typical type C particles. Nonintegrated plasmovirus DNA was not toxic for the cells and could be detected for at least 14 days post-transfection. While the transfected gag gene and the transgene could also be detected throughout this period, we observed that env-coded proteins decreased after 72 hours post-transfection. Nevertheless, the production of RV resulted in the propagation of the transgene in the culture, with stable integration of plasmovirus proviral DNA into the host genome of infected cells. We show that this propagation results in a major improvement in therapeutic efficacy using an HSV1-TK transgene and ganciclovir treatment, when compared to that of plasmovirus constructs that cannot propagate. Altogether, these results demonstrate the functionality of this gene transfer method and suggest that improvements in the vector design enhance its efficacy.

Asunto(s)

Replicación del ADN , Técnicas de Transferencia de Gen , Terapia Genética/métodos , Vectores Genéticos , Plásmidos/genética , Simplexvirus/genética , Células 3T3 , Animales , Expresión Génica , Productos del Gen gag/genética , Productos del Gen gag/metabolismo , Genes Virales/genética , Humanos , Ratones , Provirus/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Simplexvirus/metabolismo , Timidina Quinasa/genética , Timidina Quinasa/metabolismo , Transgenes , Células Tumorales Cultivadas , Integración Viral

RESUMEN

Therapeutic gene transfer has progressed quite rapidly in recent years. Noticeably, it has now reached the clinical stage in both fields of inherited and acquired diseases. Numerous studies of liver-targeted gene therapy and cancer gene therapy have supported the hope that such innovative approaches may be of help in the treatment of primary or secondary liver tumors. In this article, the main strategies of experimental, hepatic cancer gene therapy in the prospect of a clinical use are reviewed.

Asunto(s)

Terapia Genética , Neoplasias Hepáticas/terapia , Adenoviridae/genética , Carcinoma Hepatocelular/terapia , Predicción , Técnicas de Transferencia de Gen , Enfermedades Genéticas Congénitas/terapia , Vectores Genéticos , Humanos , Neoplasias Hepáticas/secundario , Oncogenes/genética , Retroviridae/genética

RESUMEN

We have generated a chimeric gene transfer vector that combines the simplicity of plasmids with the infectivity and long-term expression of retroviruses. We replaced the env gene of a Moloney murine leukemia virus-derived provirus by a foreign gene, generating a plasmid that upon transfer to tumor cells generates noninfectious retroviral particles carrying the transgene. We added to this plasmid an independent expression cassette comprising a cytomegalovirus promoter, an amphotropic retroviral envelope, and a polyadenylylation signal from simian virus 40. These constructs were designed to minimize the risk of recombination generating replication-competent retroviruses. Their only region of homology is a 157-bp sequence with 53% identity. We show that the sole transfection of this plasmid in various cell lines generates infectious but defective retroviral particles capable of efficiently infecting and expressing the transgene. The formation of infectious particles allows the transgene propagation in vitro. Eight days after transfection in vitro, the proportion of cells expressing the transgene is increased by 10-60 times. There was no evidence of replication-competent retrovirus generation in these experiments. The intratumoral injection of this plasmid, but not of the control vector lacking the env gene, led to foci of transgene-expressing cells, suggesting that the transgene had propagated in situ. Altogether, these "plasmoviruses" combine advantages of viral and non-viral vectors. They should be easy to produce in large quantity as clinical grade materials and should allow efficient and safe in situ targeting of tumor cells.

Asunto(s)

Terapia Genética , Vectores Genéticos , Retroviridae , Transfección , Replicación Viral , Células 3T3 , Animales , Antivirales/toxicidad , Bromodesoxicitidina/análogos & derivados , Línea Celular , Transformación Celular Neoplásica , Replicación del ADN/efectos de los fármacos , Desoxicitidina/análogos & derivados , Desoxicitidina/metabolismo , Ganciclovir/toxicidad , Genes env , Masculino , Ratones , Ratones Endogámicos BALB C , Virus de la Leucemia Murina de Moloney/genética , Neoplasias Experimentales/patología , Plásmidos , Provirus/genética , Proteínas Recombinantes/biosíntesis , Retroviridae/genética , Retroviridae/fisiología , Simplexvirus/enzimología , Simplexvirus/genética , Timidina Quinasa/biosíntesis , beta-Galactosidasa/biosíntesis

RESUMEN

This work was aimed at generating a novel system for gene transfer to tumor cell, combining the advantages of non-viral gene transfer methods with those of transfer by recombinant retroviruses. We replaced the env gene of an infectious Moloney murine leukemia provirus with the gene coding for the thymidine kinase of Herpes Simplex Virus 1 (HSV1-TK). The sole transfection of this construction allows the production of viral particles, and the encapsidation of a viral genome carrying transgene. We show that this gene is expressed at a level sufficient for conferring sensitivity to ganciclovir, a nucleoside analog that is metabolised in a toxic compound by HSV1-TK. We also show that the complementation of this recombinant defective provirus with a gene coding for a retroviral envelope, either expressed constitutively by the transduced cell, or by co-transfection, leads to the formation of infectious viral particles capable of transducing HSV1-TK into tumor cells.

Asunto(s)

Técnicas de Transferencia de Gen , Vectores Genéticos , Provirus/genética , Transgenes , Antivirales/farmacología , Ganciclovir/farmacología , Herpesvirus Humano 1/genética , Técnicas In Vitro , Virus de la Leucemia Murina de Moloney/genética , Recombinación Genética , Timidina Quinasa/efectos de los fármacos , Timidina Quinasa/genética

Asunto(s)

Terapia Genética/métodos , Neoplasias/terapia , Animales , Apoptosis/genética , Ensayos Clínicos como Asunto , Técnicas de Transferencia de Gen , Humanos , Neoplasias Hepáticas Experimentales/terapia , Metástasis de la Neoplasia , Ratas

RESUMEN

The herpes simplex virus type 1 thymidine kinase (HSV1-TK) converts nontoxic nucleoside analogs such as ganciclovir into phosphorylated compounds that act as chain terminators and specifically kill dividing cells. This property could be exploited for the treatment of tumors that are made up of rapidly dividing cells invading a nonproliferating tissue. For this purpose, specific expression of the suicide gene into dividing tumor cells can be further targeted by using retroviral-mediated gene transfer. We investigated whether the direct intratumoral transduction of a suicide gene might induce the elimination of malignant solid tumors. Rats with established macroscopic liver metastases were given an intratumoral injection of packaging cells producing either HSV1-TK- or lacZ-expressing recombinant retroviral particles. All rats were next treated with ganciclovir. A dramatic regression of the tumor volume was observed in the HSV1-TK-treated animals. The residual tumors were mostly made up of a massive fibrotic reaction, with the mean cancer cell mass being reduced approximately 60-fold compared to controls. In some animals, the residual tumors were devoid of cancer cells. This treatment efficacy appears in part due to a "bystander effect" in which phosphorylated ganciclovir could be transferred from cell to cell and to an active local immune reaction evidenced by massive infiltration of the tumors by macrophages and both CD4+ and CD8+ lymphocytes. This efficient therapeutic approach might be an ultimate treatment for disseminated liver metastases in humans and could also be applied to treatment of a large variety of solid tumors.

Asunto(s)

Neoplasias Hepáticas/terapia , Animales , Ganciclovir/uso terapéutico , Terapia Genética , Vectores Genéticos , Humanos , Neoplasias Hepáticas/secundario , Masculino , Metástasis de la Neoplasia , Trasplante de Neoplasias , Neoplasias Experimentales/terapia , Ratas , Retroviridae/genética , Timidina Quinasa/genética , Transfección

RESUMEN

The effects of long-term angiotensin-converting enzyme (ACE) inhibitor treatment with perindopril 2 mg/kg/day, by gavage, for 3 months on the mechanical function and structure of large arteries were studied in adult spontaneously hypertensive rats with established hypertension. Hemodynamic parameters, including instantaneous aortic blood flow and pressure, were recorded under anesthesia at the end of the treatment period. Systemic arterial compliance was calculated from aortic pressure and flow recordings; passive mechanical properties of the in situ localized carotid artery were measured. Histologic and morphologic parameters of the aortic media, including cross-sectional area and thickness, size, and density of smooth muscle nuclei and of elastin and collagen fibers, were measured using an automated image analysis system. ACE inhibitor treatment significantly decreased mean arterial pressure (-27%, p < 0.001) and total peripheral resistance (-30%, p < 0.05) while cardiac output was increased (29%, p < 0.05). Systemic arterial compliance and carotid compliance were both increased by treatment (63%, p < 0.05, and 83%, p < 0.05, respectively). Morphometric assessment of vascular structure showed that ACE inhibitor treatment significantly decreased medial cross-sectional area (-36%, p < 0.001) and thickness (-16%, p < 0.001) by affecting smooth muscle cell hypertrophy (nucleus size decreased by 26%, p < 0.05) without changes in smooth cell number. Collagen density was decreased by treatment (-42%, p < 0.05), whereas elastin density was not affected by treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Arterias/efectos de los fármacos , Hipertensión/fisiopatología , Indoles/farmacología , Animales , Aorta Torácica/efectos de los fármacos , Aorta Torácica/patología , Monitores de Presión Sanguínea , Arterias Carótidas/efectos de los fármacos , Adaptabilidad/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Hipertensión/patología , Hipertrofia/patología , Procesamiento de Imagen Asistido por Computador , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso Vascular/patología , Perindopril , Ratas , Ratas Endogámicas SHR , Resistencia Vascular/efectos de los fármacos

RESUMEN

The aim of this study was to investigate the propensity to develop cardiac arrhythmias during an acute period of ischemia between normal and hypertrophied (by means of a swimming training regimen) rat hearts. We used the coronary artery ligation in vivo technique which induced the occurrence of cardiac arrhythmias in rats that was followed by the determination of the occluded zone size. This study was coupled to an in vitro study using a two-compartment tissue bath in which half of the ventricular preparation was exposed to normal conditions and the other to ischemic conditions (low pH, hypoxia, and hyperkalemia). We also measured the collagen content and the DNA/protein ratio of the hearts. Twenty-eight male Wistar rats submitted to an eight-week swimming training (SWT) and twenty-eight cage-confined matched rats were used for the studies. SWT resulted in a 14% decrease in mean body weight and an 8% increase in absolute heart weight. We also observed a resting bradycardia in the trained animals and blood pressure remained unchanged between the two groups. Collagen content was unchanged and DNA/protein ratio was lower in the left ventricle of trained animals. During a 30-min period of coronary artery ligation, SWT rats demonstrated fewer ischemia-induced arrhythmias as compared to controls. The size of the zone affected by the vasal occlusion was lower in trained animals. Electrophysiological data recorded in the two-compartment bath showed a marked prolongation of action potential duration and refractory period in the SWT rat hearts. During the 15-min period of in vitro ischemia there was a global alteration of all electrophysiological parameters which did not differ between the two groups. Our data support the hypothesis that resting bradycardia and decrease in ischemic zone size may be involved in the arrhythmogenic protection observed in hypertrophied hearts of swimming rats after an acute ligation of the left coronary artery. Our results also indicate that cardiac hypertrophy, as defined by quantitative changes in cardiac mass or by the electrophysiological alterations that are related to its development, is not necessarily associated with an increased risk for the occurrence of arrhythmias.

Asunto(s)

Arritmias Cardíacas/etiología , Cardiomegalia/complicaciones , Potenciales de Acción , Animales , Bradicardia/etiología , Colágeno/análisis , ADN/análisis , Susceptibilidad a Enfermedades , Masculino , Isquemia Miocárdica/complicaciones , Condicionamiento Físico Animal , Ratas , Ratas Wistar

RESUMEN

We investigated whether the transduction of a suicide gene might induce the elimination of malignant solid tumours. BDIX male rats were given an intra-hepatic injection of a mixture containing DHDK12 tumor cells and xenogeneic fibroblasts. The latter were producing either the herpes simplex virus type 1 thymidine kinase HSV1-TK- or nls-lac Z(control)-expressing recombinant retroviral particles. 5 days later, a time at which the tumor is macroscopic, all the rats were treated with ganciclovir, a nucleoside analog that is metabolized by HSV1-TK into a toxic compound. After 5 days of treatment, a dramatic reduction in tumour volume was noted in the HSV1-TK group. These results delineate a new therapeutical strategy for the treatment of disseminated liver metastases or of a large variety of solid malignant tumours.

Asunto(s)

Neoplasias Hepáticas Experimentales/terapia , Transfección , Animales , Muerte Celular/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Fibroblastos/enzimología , Ganciclovir/farmacología , Ganciclovir/uso terapéutico , Neoplasias Hepáticas Experimentales/tratamiento farmacológico , Masculino , Ratas , Simplexvirus/genética , Timidina Quinasa/genética , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/enzimología

RESUMEN

The role of genetically determined immune attack and blood pressure in graft rejection-induced arterial wall injury and response was assessed by studying the compliance and changes in wall structure of aortic isografts and allografts in normotensive (Wistar-Kyoto [WKY]) and hypertensive (spontaneously hypertensive [SHR]) rats. Six groups of 8-week-old rats were compared: sham-operated in both strains, isografts, and allografts between the two strains (SHR aortas grafted in WKYs, designated SWs; WKY aortas grafted in SHRs, designated WSs; isografts in SHRs, designated SSs; and isografts in WKYs, designated WWs). Each arterial graft was studied 8 weeks after transplantation for volume and compliance (pressures of 75-175 mm Hg) under basal conditions. The amounts of collagen, elastin, and nuclei in the media and intima of the walls of control and grafted aortas were quantified morphometrically. Isografts and controls had the same mechanical characteristics under basal conditions: the arterial volume and arterial compliance of hypertensive rats were lower than those of normotensive rats (p less than 0.001). Allografts had a greater initial volume (p less than 0.001) and a lower compliance (p less than 0.001) than did isografts. Allografts in SHRs (SSs) were initially dilated, whereas allografted WKYs (WWs) were not. There was intimal proliferation in hypertensive isografts (14 +/- 0.77 microns) and in both types of allografts (WS, 69 +/- 1.55 microns; SW, 44 +/- 1.81 microns); nucleus density was higher in hypertensive allografts (WS) than in normotensive allografts (SW); and collagen density was also higher in SW than in WS allografts. Allografts had decreased medial thickness and decreased smooth muscle cell density.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Aorta/trasplante , Presión Sanguínea , Animales , Aorta/patología , Aorta/fisiopatología , Volumen Sanguíneo , División Celular , Colágeno/metabolismo , Elastina/metabolismo , Masculino , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY , Valores de Referencia , Trasplante Homólogo , Trasplante Isogénico

RESUMEN

Hemodynamic and structural changes of the heart and large arterial vessels were studied in normotensive and spontaneously hypertensive rats following 12 weeks administration of converting enzyme inhibitor (perindopril, 2 mg/kg daily by gavage). In both strains, a significant blood pressure reduction was observed. In normotensive rats, the hemodynamic changes involved significant increase in systemic arterial compliance whereas slight changes in left ventricular weight and aortic medial thickness were observed. In hypertensive rats, the increase in compliance was relatively small, whereas there was a major reduction in medial thickness. Furthermore, the reduction of the media thickness was much more pronounced than that of the left ventricular hypertrophy. The present results suggest that the cardiac and arterial changes observed following long term converting enzyme inhibition do not strictly parallel the blood pressure changes in hypertensive rats. Dissociation between cardiac and arterial changes may be observed.

Asunto(s)

Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Hipertensión/tratamiento farmacológico , Indoles/farmacología , Animales , Arterias/efectos de los fármacos , Arterias/patología , Arterias/fisiopatología , Presión Sanguínea/efectos de los fármacos , Cardiomegalia/tratamiento farmacológico , Cardiomegalia/patología , Corazón/efectos de los fármacos , Corazón/fisiopatología , Hemodinámica/efectos de los fármacos , Hipertensión/patología , Hipertensión/fisiopatología , Miocardio/patología , Perindopril , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY

RESUMEN

Relative 125I-albumin concentration was measured in vivo in the aortic media of sham-operated (n = 10) and hypertensive (two-kidney, one clip) rats, untreated (n = 8) or treated (n = 10) by an angiotensin converting enzyme inhibitor (CEI, Trandolapril). Blood pressure was acutely lowered to a normal level at the time of the experiment in hypertensive rats (n = 7) to separate the direct effect of increased pressure from the effect of pressure-induced structural changes. Relative tissue concentration profiles of labeled albumin across the media were obtained using a serial frozen-sectioning technique. In hypertensive rats, the mean medial albumin concentration decreased by 35% in the ascending arch and 32% in the descending arch (p less than 0.01). When blood pressure was acutely lowered in hypertensive animals, this value decreased further by 56% in the ascending arch, 48% in the descending arch (p less than 0.01), and 22% in the thoracic aorta (p less than 0.05) as compared with controls. The medial thickness in hypertensive rats was significantly increased (more in the ascending arch than in the rest of the aorta). Four-week CEI treatment reversed hypertension and medial thickening, but the mean medial albumin concentration remained significantly lower in the arch (by 36% in the ascending part and 40% in the descending part, p less than 0.01). The collagen content in the thoracic aorta was significantly increased in hypertensive rats (by 40%, p less than 0.01) and remained increased (by 29%, p less than 0.01) after CEI treatment. These results suggested that the hypertension-induced structural changes might reduce the medial distribution volume for albumin, whereas elevated blood pressure per se tended to enhance albumin concentration within the media. However, the net result of chronic hypertension was a reduction of the mean medial albumin concentration. The aortic arch appeared to be more affected than the rest of the aorta. Fiber content, more than medial thickness, might be responsible for the observed differences in albumin concentration. Lowering of blood pressure seemed to be insufficient to restore normal albumin concentration profiles and perhaps those of other macromolecules. This finding may be relevant in evaluating some of the complications associated with hypertension.

Asunto(s)

Albúminas/farmacocinética , Aorta/metabolismo , Hipertensión/metabolismo , Radioisótopos de Yodo , Animales , Aorta/diagnóstico por imagen , Aorta/patología , Aorta Abdominal/metabolismo , Aorta Abdominal/patología , Aorta Torácica/metabolismo , Aorta Torácica/patología , Transporte Biológico/fisiología , Enfermedad Crónica , Colágeno/análisis , Hipertensión/patología , Masculino , Cintigrafía , Ratas , Ratas Endogámicas , Distribución Tisular